E

Emcure Pharmaceuticals Ltd
NSE:EMCURE

Watchlist Manager
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Watchlist
Price: 1 314.15 INR 2.36% Market Closed
Market Cap: 248.5B INR
Have any thoughts about
Emcure Pharmaceuticals Ltd?
Write Note

Intrinsic Value

The intrinsic value of one EMCURE stock under the Base Case scenario is 1 371.66 INR. Compared to the current market price of 1 314.15 INR, Emcure Pharmaceuticals Ltd is Undervalued by 4%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

EMCURE Intrinsic Value
1 371.66 INR
Undervaluation 4%
Intrinsic Value
Price
E
Worst Case
Base Case
Best Case

Valuation Backtest
Emcure Pharmaceuticals Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for EMCURE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about EMCURE?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Emcure Pharmaceuticals Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Emcure Pharmaceuticals Ltd

Provide an overview of the primary business activities
of Emcure Pharmaceuticals Ltd.

What unique competitive advantages
does Emcure Pharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Emcure Pharmaceuticals Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Emcure Pharmaceuticals Ltd.

Provide P/S
for Emcure Pharmaceuticals Ltd.

Provide P/E
for Emcure Pharmaceuticals Ltd.

Provide P/OCF
for Emcure Pharmaceuticals Ltd.

Provide P/FCFE
for Emcure Pharmaceuticals Ltd.

Provide P/B
for Emcure Pharmaceuticals Ltd.

Provide EV/S
for Emcure Pharmaceuticals Ltd.

Provide EV/GP
for Emcure Pharmaceuticals Ltd.

Provide EV/EBITDA
for Emcure Pharmaceuticals Ltd.

Provide EV/EBIT
for Emcure Pharmaceuticals Ltd.

Provide EV/OCF
for Emcure Pharmaceuticals Ltd.

Provide EV/FCFF
for Emcure Pharmaceuticals Ltd.

Provide EV/IC
for Emcure Pharmaceuticals Ltd.

Show me price targets
for Emcure Pharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Emcure Pharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Emcure Pharmaceuticals Ltd?

What are the Net Income projections
for Emcure Pharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Emcure Pharmaceuticals Ltd?

What are the EPS projections
for Emcure Pharmaceuticals Ltd?

How accurate were the past EPS estimates
for Emcure Pharmaceuticals Ltd?

What are the EBIT projections
for Emcure Pharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Emcure Pharmaceuticals Ltd?

Compare the revenue forecasts
for Emcure Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Emcure Pharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Emcure Pharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Emcure Pharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Emcure Pharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Emcure Pharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Emcure Pharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Emcure Pharmaceuticals Ltd.

Provide ROE
for Emcure Pharmaceuticals Ltd.

Provide ROA
for Emcure Pharmaceuticals Ltd.

Provide ROIC
for Emcure Pharmaceuticals Ltd.

Provide ROCE
for Emcure Pharmaceuticals Ltd.

Provide Gross Margin
for Emcure Pharmaceuticals Ltd.

Provide Operating Margin
for Emcure Pharmaceuticals Ltd.

Provide Net Margin
for Emcure Pharmaceuticals Ltd.

Provide FCF Margin
for Emcure Pharmaceuticals Ltd.

Show all solvency ratios
for Emcure Pharmaceuticals Ltd.

Provide D/E Ratio
for Emcure Pharmaceuticals Ltd.

Provide D/A Ratio
for Emcure Pharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Emcure Pharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Emcure Pharmaceuticals Ltd.

Provide Quick Ratio
for Emcure Pharmaceuticals Ltd.

Provide Current Ratio
for Emcure Pharmaceuticals Ltd.

Provide Cash Ratio
for Emcure Pharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Emcure Pharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Emcure Pharmaceuticals Ltd?

What is the current Free Cash Flow
of Emcure Pharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Emcure Pharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Emcure Pharmaceuticals Ltd

Balance Sheet Decomposition
Emcure Pharmaceuticals Ltd

Current Assets 42.6B
Cash & Short-Term Investments 5.2B
Receivables 21.1B
Other Current Assets 16.3B
Non-Current Assets 35.5B
Long-Term Investments 199.9m
PP&E 24B
Intangibles 8.9B
Other Non-Current Assets 2.4B
Current Liabilities 32.1B
Accounts Payable 13.1B
Accrued Liabilities 1.9B
Short-Term Debt 9.6B
Other Current Liabilities 7.5B
Non-Current Liabilities 16.4B
Long-Term Debt 9.8B
Other Non-Current Liabilities 6.6B
Efficiency

Earnings Waterfall
Emcure Pharmaceuticals Ltd

Revenue
66.6B INR
Cost of Revenue
-26B INR
Gross Profit
40.6B INR
Operating Expenses
-31.5B INR
Operating Income
9.2B INR
Other Expenses
-4.2B INR
Net Income
5B INR

Free Cash Flow Analysis
Emcure Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

EMCURE Profitability Score
Profitability Due Diligence

Emcure Pharmaceuticals Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive Revenue Growth Forecast
Positive ROE
58/100
Profitability
Score

Emcure Pharmaceuticals Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.

EMCURE Solvency Score
Solvency Due Diligence

Emcure Pharmaceuticals Ltd's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Average Altman Z-Score
42/100
Solvency
Score

Emcure Pharmaceuticals Ltd's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EMCURE Price Targets Summary
Emcure Pharmaceuticals Ltd

Wall Street analysts forecast EMCURE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EMCURE is 1 703.4 INR with a low forecast of 1 676.6 INR and a high forecast of 1 764 INR.

Lowest
Price Target
1 676.6 INR
28% Upside
Average
Price Target
1 703.4 INR
30% Upside
Highest
Price Target
1 764 INR
34% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for EMCURE?

Click here to dive deeper.

Dividends

Emcure Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for EMCURE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Emcure Pharmaceuticals Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

248.5B INR

Dividend Yield

0%

Description

Emcure Pharmaceuticals Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Pune, Maharashtra and currently employs 11,146 full-time employees. The company went IPO on 2024-07-10. Emcure Pharmaceuticals Ltd is an India-based pharmaceutical company. The firm is engaged in developing, manufacturing and marketing a range of pharmaceutical products across several therapeutic areas. The company offers a range of products and services under formulations, biologics, and Active Pharmaceutical Ingredients (APIs). The company focuses on various key therapeutic areas, such as gynecology, cardiology, anti-infective, diabetes, biologics, mRNA vaccines, and vitamin, minerals and nutrients. The company offers products in both, chronic and acute segments. The firm's subsidiary, Gennova Biopharmaceuticals Limited, is a biotechnology company dedicated to developing, producing, and commercializing bio-therapeutics to address life-threatening diseases across various indications. The company has developed two platforms: Mammalian and Microbial. Its key APIs consists of S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate, and Eribulin. The company operates approximately 13 manufacturing facilities.

Contact

MAHARASHTRA
Pune
Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi
+912035070033
www.emcure.com

IPO

2024-07-10

Employees

11 146

Officers

CEO, MD & Executive Director
Mr. Satish Ramanlal Mehta
Chief Financial Officer
Mr. Tajuddin Sabir Shaikh
President of Operations & Whole-Time Director
Mr. Samit Satish Mehta
Chief Scientific Officer & Whole-Time Director
Dr. Mukund Keshao Gurjar
Executive Director of Projects & Whole-Time Director
Mr. Sunil Rajanikant Mehta
Executive Director of India Business & Whole-Time Director
Ms. Namita Vikas Thapar
Show More
Company Secretary & Compliance Officer
Mr. Chetan Rajendra Sharma
Director of Corporate Communications & Public Relations
Mr. Naveen Soni
President of Corporate Development, Strategy & Finance
Mr. Vikas Madan Thapar
Executive Vice President of Human Resources
Mr. Rajesh Nair
Show Less

See Also

Discover More
What is the Intrinsic Value of one EMCURE stock?

The intrinsic value of one EMCURE stock under the Base Case scenario is 1 371.66 INR.

Is EMCURE stock undervalued or overvalued?

Compared to the current market price of 1 314.15 INR, Emcure Pharmaceuticals Ltd is Undervalued by 4%.

Back to Top